A recent article was recently made on gazetteday.com concerning Paul Mampilly sharing his secrets on investment success with his 60,000 subscribers of his newsletter. Mampilly writes the leading investment industry newsletter called Profits Unlimited. He was encouraged to continue to offer investment recommendations monthly as he reached 60,000 subscribers. His newsletter is really successful due to his proven success and his useful and detailed information.

Published through Banyan Hill Publishing, Profits Unlimited has been circulating for approximately a year. Mampilly’s subscribers can visit his site for stock tracking after they receive his newsletter. He teaches subscribers so they can be smart investors.

Banyan Hill Publishing concentrates on publishing research advisories and investment newsletters. Being an independent publishing house, this organization has 200,000 subscribers. Its name is representative of a tree that stands strong even when upon enduring catastrophic natural disasters, and they are conveying to their readers to be like banyan trees. One or more financial storms will happen, and they just want their readers to have the tools and news needed to sustain and continually grow.

About Paul Mampilly

The founder of Capuchin Consulting, Mampilly has been a hedge fund manager who won many awards which include the Templeton Foundation investment competition. He has been seen on several television broadcasts on CNBC, Bloomberg TV, and other networks. He also found Profits Unlimited in which he provides guidance to interested readers wanting to learn more about stocks and when to invest or get away from investing in tech stocks.

He has around 25 years of experience as a businessman after he moved at a young age from India. In 1991, he began a financial and business career at the Deutsche Bank where he managed millions of dollars in accounts and startup accounts. He also worked at the Royal Bank of Scotland in managing accounts. He later became the hedge fund manager for Kinetics International Fund in which he created great success. He also invested in an organization that developed a drug that assists in treating muscular dystrophy. He then sold his Sarepta Therapeutics share in under a year for over a 2000 percent gain. He also invested in Netflix in 2008 where he saw significant gain before walking away.